Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib.

@article{Padera2008DifferentialRO,
  title={Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib.},
  author={Timothy P. Padera and Angera H. Kuo and Tohru Hoshida and Shan Liao and Jennifer M. Lobo and Kevin Kozak and Dai Fukumura and Rakesh K. Jain},
  journal={Molecular cancer therapeutics},
  year={2008},
  volume={7 8},
  pages={2272-9}
}
Blood vessels are required for a tumor to grow and functional lymphatic vessels are required for it to disseminate to lymph nodes. In an attempt to eradicate both the primary tumor and its lymphatic metastasis, we targeted both blood and lymphatic vessels using two different tyrosine kinase inhibitors (TKIs): cediranib and vandetanib, which block vascular endothelial growth factor receptor (VEGFR)-2 and -3 in enzymatic assays. We found that although both cediranib and vandetanib slowed the… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Similar Papers

Loading similar papers…